Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

REINACH, Switzerland, September 24 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced the completion of enrolment in the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI).

The trial was designed as a multi-centre, double-blind comparative study. Patients suffering from cSSSI received intravenous (IV) vancomycin for the first two days of treatment and were then randomised to either continue to receive IV vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients have been randomised for this study.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with IV vancomycin in the treatment of cSSSI. The primary endpoint is the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcome as well as safety and tolerability.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The speed of enrolment in this Phase II trial surpassed our expectations. It again shows that an 'intravenous-to-oral' step-down therapy serves a medical need and could add significant value to intravenous iclaprim. Marketing applications for intravenous iclaprim have been filed in the U.S.A., the European Union and Canada. We will release the top-line data of this Phase II switch study in the coming months and subsequently determine the path ahead."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product can
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Research and ... "Global Ophthalmic Diagnostic Devices Market 2014-2018" report to ... About Ophthalmic Diagnostic Device ... to identify a defect or deficiency in the human ... ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal disorders, ...
(Date:7/25/2014)... , July 25, 2014 Leading events ... is returning for the seventh year to São Paulo, ... th August 2014. The event will co-locate with Food ... most comprehensive meeting point for the pharmaceutical industry. ... 25 countries for pharmaceutical sales are now exploring the ...
(Date:7/24/2014)... Calif. , July 24, 2014   AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today confirmed the PDUFA date for Zalviso remains ... that a rumor circulated online stating the Food and ... 24, 2014 there has been no notification to the ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... BOSTON, Dec. 9 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... sales for the month of October 2009 and $42,898.42 in ... October 2008 and $32,028.52 for November 2008 respectively. , About ... instrument company whose mission is to develop and market breakthrough ...
... , , , GAITHERSBURG, Md, ... in the development and manufacture of lentiviral gene delivery ... Institutes of Health (NIH) small business innovation research (SBIR) ... Generating Hepatitis C Virus-Like Particles using Lentivirus". In ...
Cached Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:7/27/2014)... 2014 The constant expansion of companies ... demand for enterprise video. Additional factors that have increased ... areas such as corporate communication, learning and development, security ... all these factors the enterprise video market value has ... reach $35.57 billion in 2018 with a compound annual ...
(Date:7/27/2014)... 27, 2014 The North American security ... at $1570 million in 2014, and it is expected ... of 4.64%. The report incorporates the factors that influence ... of growth rates and projected total expenditure. The report ... global markets. Apart from the general overview of the ...
(Date:7/27/2014)... York City (Sunday July 27 11:45 am ... operationsinfection at the surgical sitehas been reduced by ... participation in the American College of Surgeons National ... a new case study presented at the 2014 ... Vancouver, British Columbia, reportedly reduced its rate of ...
(Date:7/27/2014)... The report provides market analysis ... Market Analysis (Commercial Aviation And Defense Aviation Landing ... - Forecasts 2014 - 2019." The report covers ... shape the market during the study period. It ... that are currently prevailing in the global market. ...
(Date:7/27/2014)... 2014 As Tylenol lawsuits ... move forward in federal court, Bernstein Liebhard LLP ... of the benefits purportedly associated with acetaminophen, the ... which appears in the The Lancet, looked at ... whom were given either acetaminophen or a placebo ...
Breaking Medicine News(10 mins):Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4
... 13 Berkery Noyes announced today that,the firm represented ... HCPro Holdings, Inc. to Halyard Capital. The management team ... Terms of the transaction,were not disclosed., "This is ... team with a winning healthcare and information franchise," said,Tom ...
... with glasses brought them up to snuff with ... News) -- Preschoolers with poor vision significantly improved ... wearing prescription glasses, a new study shows. , ... have early vision problems that are undiagnosed and ...
... Inc.,(Nasdaq: TSTF ), a national provider of ... has hired Jeff Davis as Director,of Operations for ... will be responsible for leading client field,operations and ... existing and new contracts. Mr. Davis will report ...
... Healthcare Industry to Follow Suit, WASHINGTON, Feb. ... to require all of its administrative,data-exchange vendors to ... Committee on Operating Rules for Information Exchange (CORE), ... electronic administrative data,exchange," said Ronald A. Williams, CAQH ...
... healthcare privacy auditing solutions, ... titled Addressing Electronic Health Record Privacy and ... HIMSS Chairman & Vice ... Robert Sullivan of PricewaterhouseCoopers, Healthcare Advisory ...
... Enters Into Marketing Partnership for Once-Daily Tramadol for ... ... Feb. 13 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today announced ... Food and Drug Administration,which allows for the marketing and sale of ...
Cached Medicine News:Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 3Health News:Fixing Poor Vision Boosts Preschoolers' Test Scores 2Health News:TeamStaff Hires Jeff Davis as Director of Operations for Government Solutions Subsidiary 2Health News:TeamStaff Hires Jeff Davis as Director of Operations for Government Solutions Subsidiary 3Health News:Aetna Requires CAQH Core Rules Certification for Vendors 2Health News:Aetna Requires CAQH Core Rules Certification for Vendors 3Health News:FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges 2Health News:Labopharm's Once-Daily Tramadol Approved in South Korea and Australia 2Health News:Labopharm's Once-Daily Tramadol Approved in South Korea and Australia 3
... objective and high power negative lens delivering ... true benefit of this system is ease ... is made possible due to a superior ... bar and individual interpupillary adjustment provides stability ...
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Signa Profile is built on the Signa foundation to deliver speed & image quality....
... Platelet Concentrate System is a point-of-care system ... Concentrate (also referred to as Platelet Rich ... (PPP) from a small sample of blood. ... growth factors, which are found in the ...
Medicine Products: